<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Silo Pharma, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/silo-pharma-inc</link>
    <description>Latest news and press releases for Silo Pharma, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 22 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/silo-pharma-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d783e851cc36e475342d3c.webp</url>
      <title>Silo Pharma, Inc.</title>
      <link>https://6ix.com/company/silo-pharma-inc</link>
    </image>
    <item>
      <title>Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-announces-strategic-business-expansion-into-multi-billion-dollar-ai-agent-market-with-acquisition-of-managed-ai-agent-platform-qwikagents</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-announces-strategic-business-expansion-into-multi-billion-dollar-ai-agent-market-with-acquisition-of-managed-ai-agent-platform-qwikagents</guid>
      <pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
      <description>Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE</description>
    </item>
    <item>
      <title>Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy-1</guid>
      <pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
      <description>EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE</description>
    </item>
    <item>
      <title>Silo Pharma Announces Share Buyback Program</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-announces-share-buyback-program-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-announces-share-buyback-program-1</guid>
      <pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
      <description>Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-receives-notice-of-allowance-in-japan-for-spc-15-expanding-global-intellectual-property-portfolio-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-receives-notice-of-allowance-in-japan-for-spc-15-expanding-global-intellectual-property-portfolio-1</guid>
      <pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
      <description>Patent strengthens protection for novel PTSD drug and advances the Company’s international IP strategy SARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo</description>
    </item>
    <item>
      <title>Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-executes-letter-of-intent-with-allucent-to-support-phase-1-clinical-development-of-spc-15-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-executes-letter-of-intent-with-allucent-to-support-phase-1-clinical-development-of-spc-15-1</guid>
      <pubDate>Tue, 30 Dec 2025 05:00:00 GMT</pubDate>
      <description>Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma,</description>
    </item>
    <item>
      <title>Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-partners-with-allucent-to-support-planned-fda-investigational-new-drug-application-for-spc-15-as-a-therapeutic-for-ptsd-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-partners-with-allucent-to-support-planned-fda-investigational-new-drug-application-for-spc-15-as-a-therapeutic-for-ptsd-1</guid>
      <pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
      <description>SARASOTA, FL, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical</description>
    </item>
    <item>
      <title>Silo Pharma Selects Alphaledger’s T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-selects-alphaledgers-t12-fund-for-tokenized-real-world-asset-investments-on-solana-blockchain-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-selects-alphaledgers-t12-fund-for-tokenized-real-world-asset-investments-on-solana-blockchain-1</guid>
      <pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
      <description>Investment vehicle provides diversified exposure to real-world assets and expected to reduce portfolio volatility Strategic allocation aligns with Silo’s</description>
    </item>
    <item>
      <title>Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-issues-update-on-milestone-achievements-in-ptsd-drug-development-and-new-digital-assets-treasury-program-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-issues-update-on-milestone-achievements-in-ptsd-drug-development-and-new-digital-assets-treasury-program-1</guid>
      <pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
      <description>Significant milestones are approaching in drug development; additional digital asset purchases expected Preparation for FDA IND application expected to</description>
    </item>
    <item>
      <title>Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company’s Commitment to Multi-Chain Growth</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-expands-crypto-treasury-with-first-strategic-bitcoin-purchase-reinforcing-companys-commitment-to-multi-chain-growth-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-expands-crypto-treasury-with-first-strategic-bitcoin-purchase-reinforcing-companys-commitment-to-multi-chain-growth-1</guid>
      <pubDate>Wed, 08 Oct 2025 04:00:00 GMT</pubDate>
      <description>SARASOTA, FL, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical</description>
    </item>
    <item>
      <title>Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-acquires-researchcoin-rsc-crypto-tokens-in-support-of-decentralized-science-desci-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-acquires-researchcoin-rsc-crypto-tokens-in-support-of-decentralized-science-desci-1</guid>
      <pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
      <description>Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian</description>
    </item>
    <item>
      <title>Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-announces-closing-of-dollar25-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-announces-closing-of-dollar25-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-1</guid>
      <pubDate>Wed, 01 Oct 2025 04:00:00 GMT</pubDate>
      <description>SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-announces-dollar25-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-announces-dollar25-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-1</guid>
      <pubDate>Tue, 30 Sep 2025 04:00:00 GMT</pubDate>
      <description>SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-updates-strategic-agreement-with-fireblocks-to-secure-crypto-treasury-management-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-updates-strategic-agreement-with-fireblocks-to-secure-crypto-treasury-management-1</guid>
      <pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
      <description>Fireblocks is a globally recognized leader in the digital assets space, facilitating the secure transfer of more than $10 trillion to date SARASOTA, FL, Sept.</description>
    </item>
    <item>
      <title>Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-signs-strategic-agreement-with-fireblocks-to-advance-crypto-treasury-strategy-acquisition-and-security-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-signs-strategic-agreement-with-fireblocks-to-advance-crypto-treasury-strategy-acquisition-and-security-1</guid>
      <pubDate>Tue, 23 Sep 2025 04:00:00 GMT</pubDate>
      <description>Highly secure, institutional-grade infrastructure supports Bitcoin, Ethereum and Solana treasury strategy SARASOTA, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) --</description>
    </item>
    <item>
      <title>Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-announces-initial-investment-in-ethereum-and-solana-under-cryptocurrency-treasury-strategy-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-announces-initial-investment-in-ethereum-and-solana-under-cryptocurrency-treasury-strategy-1</guid>
      <pubDate>Tue, 16 Sep 2025 04:00:00 GMT</pubDate>
      <description>Strategic capital deployment advances Company’s blockchain treasury model and biopharma development initiatives SARASOTA, FL, Sept. 16, 2025 (GLOBE NEWSWIRE)</description>
    </item>
    <item>
      <title>Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-adds-japanese-patent-to-expanding-global-ip-portfolio-for-licensed-ptsd-drug-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-adds-japanese-patent-to-expanding-global-ip-portfolio-for-licensed-ptsd-drug-1</guid>
      <pubDate>Tue, 09 Sep 2025 04:00:00 GMT</pubDate>
      <description>SARASOTA, FL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage</description>
    </item>
    <item>
      <title>Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-secures-australian-patent-covering-licensed-ptsd-drug-candidate-expanding-global-ip-portfolio-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-secures-australian-patent-covering-licensed-ptsd-drug-candidate-expanding-global-ip-portfolio-1</guid>
      <pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
      <description>SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage</description>
    </item>
    <item>
      <title>Silo Pharma’s PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharmas-ptsd-candidate-spc-15-achieves-positive-safety-milestone-paving-way-for-accelerated-clinical-trials-under-505b2-pathway-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharmas-ptsd-candidate-spc-15-achieves-positive-safety-milestone-paving-way-for-accelerated-clinical-trials-under-505b2-pathway-1</guid>
      <pubDate>Tue, 19 Aug 2025 04:00:00 GMT</pubDate>
      <description>SPC-15’s intranasal spray formulation meets safety standards for clinical trial development SARASOTA, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.</description>
    </item>
    <item>
      <title>Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-appoints-crypto-infrastructure-pioneer-corwin-yu-to-launch-institutional-bitcoin-ethereum-and-solana-treasury-platform-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-appoints-crypto-infrastructure-pioneer-corwin-yu-to-launch-institutional-bitcoin-ethereum-and-solana-treasury-platform-1</guid>
      <pubDate>Tue, 05 Aug 2025 04:00:00 GMT</pubDate>
      <description>Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.</description>
    </item>
    <item>
      <title>Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15</title>
      <link>https://6ix.com/company/silo-pharma-inc/news/silo-pharma-announces-completion-of-dosing-in-safety-study-of-ptsd-drug-spc-15-1</link>
      <guid isPermaLink="true">https://6ix.com/company/silo-pharma-inc/news/silo-pharma-announces-completion-of-dosing-in-safety-study-of-ptsd-drug-spc-15-1</guid>
      <pubDate>Wed, 16 Jul 2025 04:00:00 GMT</pubDate>
      <description>SARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company</description>
    </item>
  </channel>
</rss>